C-Note

Hummingbird
Gold Member
The reading I did on rare earths led me down a rabbit hole the last couple of days into researching penny mining (ores and minerals) stocks in general, of which there are quite a few out there. It seems to me that the market, at least as far as mining stocks, is fairly efficient at telling you how risky a mining stock is by its share price.

If a mining stock is valued below a dollar, and has been there for awhile, it usually means that the company has not made any profit, and usually little-to-no revenue, for more than a year and has no reasonably foreseeable prospects of making any significant revenue for the intermediate (1-3 years) future. Mining stocks valued from $1-2.50 are usually making some consistent revenue, and perhaps a small profit, and/or look to have a good chance at some moderate revenue in the immediate future (1-2 years). Mining stocks valued at $3-5 are usually making a consistent, albeit moderate, profit or else appear to have a chance at a decent profit in the immediate future.

Because the price of gold is fairly high right now, it's attracting quite a few small-time mining companies to explore for gold deposits in various places around the world, including Arizona, Nevada, Mexico, and Canada. Most of their share prices are below a dollar. I looked at around 30 companies today in that category. Obviously, if you buy 10,000 shares in some mining company in Nevada at $.25 and they hit the motherlode, you just beat the market like a boss. But, how many of those 30 companies are going to find a rich vein before running out of money to fund their exploration and mine preparation? Most of them won't. Some of them, from what I've read, are hoping to find some good prospects and then sell their claim to a bigger mining company for a lump sum or interest in the resulting harvest.

There appear to be some "cheats," although not certain. I found an academic paper (and now I can't find the link), that concluded that the best value in mining prospects was in Africa. If that's true, then it might lower risk to invest in mining companies that are in Africa. However, political instability is one of the biggest risks with mining stock. Some other sources said that copper mining actually offered the best value, because copper goes for a good price and copper veins usually last longer and produce more consistent ore quality and quantity than other precious metals.

I think, though, that one good guide with penny mining stocks if you want to find some good value, but lower your risk of blowing money on mines that never go anywhere, are looking at mining stocks that are in the $1-5 range. I'm willing to be corrected, of course.
 
Last edited:
This guy just did a helluva job on DD for NOHO. Read thru if interested.


Kinda torn on this one.. On the one hand, I bought a bunch of noho the other day (and thank you for the suggestions!), but reading through this DD, it sounds like every business goal of this company is tied into the WEF great reset agenda.

It's like I'm financing my own enslavement, or at very least cheering on the system that will soon be inescapable. I suppose if this system truly is inescapable then I'd rather profit off of it than not, but for every reason other than financial, I want this company (and all others like it) to fail.

All that aside, the DD points out that they have billions of shares in total.. How often do unknown stocks with such dilution ever reach multi-dollar share prices? Genuinely curious. I'm a fairly novice investor.
 

rainy

Kingfisher
Kinda torn on this one.. On the one hand, I bought a bunch of noho the other day (and thank you for the suggestions!), but reading through this DD, it sounds like every business goal of this company is tied into the WEF great reset agenda.

It's like I'm financing my own enslavement, or at very least cheering on the system that will soon be inescapable. I suppose if this system truly is inescapable then I'd rather profit off of it than not, but for every reason other than financial, I want this company (and all others like it) to fail.

All that aside, the DD points out that they have billions of shares in total.. How often do unknown stocks with such dilution ever reach multi-dollar share prices? Genuinely curious. I'm a fairly novice investor.
I am no fan of China! Or current politics, anywhere. But I figure if I can make enough off China and others in the markets to not be dependent on the economy, great. For myself and my family. I simply want a large house, land, room to grow fruits/veggies in the country and fly business class back and forth to Europe whenever I feel like it. Live outside the machine. And start non-profits and give back. Money, family. Charity. And live outside the system. That's what I want. Can't secure the family and provide major charity without money.

TSNP had a great run from pennies to $6 dollars recently and had a reverse split. I expect a few others to run similarly. OTC is begging to run once the MM's stop f'ing with it. The new stimulus will pump 1 Billion+ into it.
 

C-Note

Hummingbird
Gold Member
Supposedly, copper will be one of the metals that does well over the next year as heavy industry ramps back up in the wake of the pandemic. I am not recommending the two copper mining companies below as a "buy," but I'm going to be looking into them to see if they're worth an investment:

- Capstone Mining Corp; CSFFF. $3.74

- Copper Mountain Mining Corp; CPPMF. $3.05
 
Last edited:

C-Note

Hummingbird
Gold Member
I've been enjoying myself researching and putting some money into penny stocks. I think I'm up to 10 stocks now. One interesting thing I've noticed is that with over-the-counter (OTC) stocks sometimes no one wants to sell their shares to you. It has happened to me six times now that I've submitted a buy order through Vanguard for OTC stocks, always at market price, and the order has gone unfulfilled.

Anyway, I figured I'll start sharing here what I find with my due diligence. The last couple of days I've been researching two Canadian companies exploring for gold in Japan: Japan Gold Corp (JGLDF) and Irving Resources (IRVRF). Based on what I've found I've rated one a "pass" and the other a "maybe." I'll post my research when I have a little more time.
 

C-Note

Hummingbird
Gold Member
OK, here's what I've learned about these two companies:

Irving Resources- IRVRF (OTC), $1.60 (US)

Japan Gold Corp- JGLDF (OTC), $.30 (US)

Based on my research, it appears that Irving (IR) is the "A" team and JG the "B" team when it comes to new gold exploration in Japan. IR is backed by Newmont Goldcorp and JG by Barrick. If I understand correctly, Newmont is a bigger player in gold mining than Barrick.

Newmont is funding IR's exploration by purchasing new IR stock at market prices, plus having "first refusal" rights on any IR claims that go into mining production. Barrick is funding JG's exploration with direct cash infusions in exchange for 51-75% interest on any subsequent production. I may be wrong, but it seems like IR's relationship structure with Newmont is more financially advantageous, as it gives IR more room to secure greater interest in any future production from their claims.

IR has more Japanese in its executive positions than JG. Also, IR has already incorporated a Japanese subsidiary while JG has not yet done so, it appears. This is important as Japan requires all foreign public corporations operating inside Japan to have a separate corporate structure under Japanese business law to operate in Japan.

IR has issued about 60 million shares of stock, while JG has issued 176 million. If I understand this correctly, this helps IR's shares be more valuable, because of the scarcity factor, among other things. JG has been much more ambitious in their exploration inside Japan, and may have burned through more money because of it, but I didn't check that. IR is more focused with their exploration, which may be good or bad.

Both companies have posted what they claim is the results from their exploration so far on their websites. Those numbers are Greek to me. I'm assuming that if Newmont and Barrick are willing to invest millions of dollars into these two companies, that it means the numbers are fairly good.

I think this is a good example of the market signaling, accurately, which stock is likely the safer and better investment. For IR's stock price to be above $1 when they have yet to produce any revenue signals reasonable confidence in their potential. Japan is an emerging market in gold exploration and production, so if you're looking to diversify your holdings in precious metals mining, I think both companies offer some good potential, but Irving appears, as of right now, to have the advantage.
 

eradicator

Peacock
Gold Member
Nice thread...in. I have a TD Ameritrade account and was thinking of easing into some trading. A few questions for the more experienced.

8. Is shorting ever a good idea?

if you time it right then sure. Like when we get big news about corona travel bans of March 2020, if you short airlines, cruise line companies and similar companies before the big announcement you can make a killing when you buy back at a much lower price
 

rainy

Kingfisher
I hope the MM's let the OTC run sometime soon. Been holding the market down with their games. PHIL should be current next month, the 2019 10K was released, another CC tomorrow. Pretty bullish on this and hold until stock dividend this summer at the earliest. Still holding HCMC. NOHO is a risk as we await some news but incredible potential.

I'm entering a position on AZFL tomorrow. New labs(9)/equipment opening this spring, partnerships in the MJ industry in the US and Mexico- incredibly strong connections within Mex at high levels where they just legalized. Have restructured management and brought in some real talent. New director is a casino mogul in Mex and major investor in AZFL. Raul Rocha. Supposed to go pink this week.

Mex might become the largest legal MJ industry globally. AZFL appears on planning on becoming Mexico's version of Canada's Tilray and Aurora. I'm not sure what the potential is here as we're on the cusp of the MJ gold rush but Tilray almost hit $70 SP and Aurora $19 SP within the last 6 months. And we aren't at widespread legalization yet. Some of these players will be trading north of $50 SP.
 
Last edited:

rainy

Kingfisher
AZFL. You don't see too many companies on the OTC making moves like this, have a platform this large and doing it in an industry which is about to explode.

 

C-Note

Hummingbird
Gold Member
I think my self-built penny stock index fund has enough mining stocks for now, so I'm moving on to pharmaceuticals and biotech. I notice already that pharm and biotech stocks get A LOT more attention from stock analysts and investors than mining stocks. I assume it's because the former have more potential for stratospheric gains in valuation if they find a "wonder drug." Because of that, I think it may be a little harder to find a good value-buy with medical penny stocks than mining stocks, because the med stocks are more attractive to speculators. Also, whenever a medtech company has a failed clinical trial, they usually have to issue a ton more shares to raise more money, which means their stock is susceptible to dilution by excessive availability. Medtech stocks are frequently on the radar at WSB as meme candidates (such as Jaguar JAGX). Anyway, I'll detail some of what I find as I do my research.

Onconova Therapeutics- ONTX - $1.12 (NASDAQ)- This company has several anti-cancer drugs in the pipeline that work by blocking cellular signaling. Apparently, this is a fairly new approach to treating cancer (last 10 years) and there are a number of companies trying to develop drugs or treatments using this method. Onconova's financials show them as receiving some revenue (but not profit), which I don't fully understand because they don't appear to have any actual drugs that have finished trials and are on the market. Without looking deeper, the revenue may be from partnerships, grants, and contracts they have with other companies and government institutions. The company's share availability/dilution, as with many medtech companies, is high at 209 million shares. Their drugs appear to be moderately promising but not groundbreaking. At $1.12 this stock is probably mildly-to-moderately overvalued right now, but the company seems to have a reasonable chance at turning at least a small profit within a couple of years if their drugs work and are competitive with the same types of treatment introduced by their competitors.

VistaGen- VTGN- $2.35- This small company has three anti-anxiety drugs going through clinical trials, with one entering Phase III. They claim in their financials to have lower development costs than the industry average, perhaps because all three of their drugs are nose sprays, rather than injections, IV, or pills. They have 141 million shares outstanding, which seems to be better than the industry average. I believe an anti-anxiety nose spray would make them an industry leader, because I'm unaware of another such nose spray on the market. Thus, this company may be a better bet than many other medtechs. I haven't decided yet if I'm going to buy it or not, but it will likely be one of my higher candidates.
 
Last edited:

aeroektar

Pelican
Anyone holding or looking into EEENF? Oil exploration/prod. company trading at around ¢.025 currently (.015 over the weekend, shot up Monday morning) that is sitting on a lot of oil, way more then MDMP which is trading at ¢.48. think I'm gonna place a limit order for ¢.015 and see what happens. Put all my stimmy into PHIL and AZFL this morning.
 

GreyStar

Chicken
Anyone holding or looking into EEENF? Oil exploration/prod. company trading at around ¢.025 currently (.015 over the weekend, shot up Monday morning) that is sitting on a lot of oil, way more then MDMP which is trading at ¢.48. think I'm gonna place a limit order for ¢.015 and see what happens. Put all my stimmy into PHIL and AZFL this morning.
I have only briefly looked into this, but from what i did read is that they have not found anything yet, so its a gamble.
However did i invest into the following Oil/Gas companies.
I3 Energy - ITE.TO
http://www.kereport.com/2021/03/11/doc-jones-research-report-on-i3-energy/

Trillion Energy - TCFF

See more infos on
 

C-Note

Hummingbird
Gold Member
The major precious metals companies are fairly well-known, but there are a number of penny stock companies that are under the radar. I mentioned the two Japanese ones earlier in this thread. From what I've found researching penny exploratory mining companies, most of them spend years issuing stock and burning through millions of dollars boring holes and taking samples and nothing ever comes of it. In North America, the onerous environmental regulations and higher labor costs torpedo the projects unless they hit a really promising vein. If they find the motherlode, one of the major players will usually jump in and partner with them to develop it further, in exchange for a controlling interest. Here is a list of the smaller mining companies I found in precious metals. Some of them are actually mainly looking for copper or uranium, but harvest gold and silver as a side project because those metals are often found together.

- Pacific Booker Minerals
- Bell Copper Corp
- Americas Gold & Silver
- Impact Silver Corp
- Globex Mining
- Cordoba Minerals
- Abacus Mining
- Wallbridge Mining
- Pacton Gold
- Lion Ore Metals
- Walker River Resources
- Harte Gold Corp
- Newrange Gold Corp
- iMetal Resources
- Gowest Gold
- Anaconda Mining
- Orestone Mining
- Viva Gold
- Radius Gold
- Westhaven Gold
- BTU Metals
- Nighthawk Gold
- Max Resources
- Minera Alamos
- First Quantum Minerals
- Fission Uranium
- Lomiko Resources
- Ivanhoe Mines
- Anglesey Mining
- Capstone Mining
- Copper Mountain Mining
- Orocobre
- Iluka Resources
- Walcott Resources
- Maple Gold Mines
- Iamgold Corp (not a penny stock)
- Northern Dynasty Minerals (WSB has talked about this one in the past)
- Freeman Gold
- New Gold Inc
- Great Panther Mining
- McEwan Mining
- Lakeshore Gold Corp
- Advance Gold Corp
- Copper Fox Metals
- Forum Uranium Corp
- Gold Reserve Inc
- Claude Resources
- Metallica Minerals
- First Majestic Silver Corp
- Fortuna Silver Mines
- Eskay Mining
- Eloro Resources
- Irving Resources
- Japan Gold
 

C-Note

Hummingbird
Gold Member
Here are the penny stocks I ended up investing in and will likely hold for at least two years, unless they really start to go south. I looked at around 100 penny stock companies, and narrowed it down to this many. My criteria for selection was two questions: (1) Does this company have a reasonable chance of accomplishing their business plan, and (2) once they accomplish it, will their plan enable their stock to appreciate to at least $10 in value per share? One of the major criteria, as I see it, for answering the two questions is the number of shares outstanding. If a company has issued too many shares, it means they're burning too much money for the size of their market capitalization and the result will be excessive dilution of their ultimate share value. Of course, these companies, being penny stocks, are still very speculative in nature and therefore I'm not recommending them as a buy, but would recommend them as deserving a second look. I only bought a few shares at first, and plan on "buying the dips" for the next year or so in order to dollar-cost-average them.

AIM Immutech- AIM- Medicine
Baudax Bio- BXRX- Medicine
Boxlight Corp- BOXL- Educational technology
Capstone Mining- CSFFF - I violated my criteria with this one as I neglected to check how many shares they had outstanding before purchase. They have 410 million shares which I think is way too many for their size, even though otherwise they appear to be a very solid mining company. Therefore, unless they do a consolidation, I don't see how their stock can get any higher than about $5-7 in valuation. So, I'll probably hold them for a year and pester them to do a stock buyback and go from there.
Celsion- CLSN- Medicine
Citius Pharm- CTXR- Medicine
Cordoba- CDBMF- Should be opening a gold mine in Colombia in about 3 years and are exploring a fairly promising copper claim with a smaller partner, Bell Copper, in Arizona. Recently, the police actually raided their property in Colombia to evict claim jumpers which seems to be a good sign that the government there is looking out for their foreign investors, unlike the government of Mexico (see Americas Gold & Silver below)
Invivo Therapeutics- NVIV- Medicine
Irving Resources- IRVRF- Gold mining in Japan
Japan Gold Corp- JGLDF- Same
Oncolytics Biotech- ONCY- Medicine
Pacific Booker Materials- PBMLF- About to open a copper, gold, and silver mine in British Columbia.
Plymouth Rock Tech- PLRTF- Security and bomb detection systems using sensors and software. I'm hoping that a larger company, like Raytheon, will buy them out which would be a massive payday.
Rare Element Resources- REEMF- Rare earth mine in Wyoming. Likely several years from production.
Solitario Zinc- XPL- Prospecting company with several good leads
Stonebridge Biopharma- SBBP- Medicine
Texas Mineral Resources- TMRC- Rare earths in Texas. A few years away from any production.
Tiziana Life Sciences- TLSA- Medicine
Vistagen Therapeutics- VTGN- Medicine
Waitr Holdings- WTRH- Food delivery. They've lost some market share, but they made a net profit for the first time in 2020, so I'm giving them a chance to see if they can keep progressing.

These are companies I'm watching but haven't decided yet if I'll be investing in them:

Abacus Mining- ABCFF- They were at the point of starting a copper and gold mine in British Columbia until the government "Secretary of Environmental and Climate Change Concerns" (seriously?) nixed their permit. So now, they're trying to get a mine started at two locations in Nevada.
Americas Gold & Silver- ARCA/USAS- Have a gold mine in operation in Nevada, two prospects in Idaho, and several mines in Mexico. Unfortunately, one of their main mines in Mexico has been shut down for three years by a criminal gang and the Mexican government has declined to intervene. Apparently, Trudeau is unable or unwilling to intervene with the Mexican president on their behalf. Sad!
Impact Silver Corp- ISVLF/IPT- Owns three mines, two processing plants, and some other potential claims in Mexico. Shut down production in 2020 and hasn't resumed in full yet. I'm not sure why this stock is so cheap but the Street must know something I don't.
Globex Mining Enterprises- GLBXF/GMX- Ore hustlers. They make claims and partner with others to explore and exploit them. They've been around for 20 years but their stock has never risen above $5, so I don't know how promising the future is for this company, but I'll keep watching them.
Orbital Engineering- OEG- Natural gas mining equipment. Will the Biden Administration keep these guys down?
VerifyMe- VRME- Tiny company that could skyrocket if their security software and systems take off, which it seems it might.
Atyr Pharma- LIFE- Medicine
USA Rare Earths- Private company which may issue an IPO this year.
Mereo BioPharm- MREO- Medicine
Verastem- VSTM- Medicine
Ovid Therapeutics- OVID- Medicine
Rigel Pharm- RIGL- Medicine
Selecta BioSciences- SELB- Medicine
Bellus Health- BLU- Medicine
Catalyst Pharm- CPRX- Medicine
Specturm Pharm- SPPI- Medicine
Globalstar- GSAT- Spent billions putting a communications satellite constellation into space, and now can't find any customers. This is one of those situations in which someone big could suddenly decide they can use their systems, and the stock price will skyrocket overnight. Who knows?
Resonant- RESN- Marketing radio spectrum technology for use with other wireless applications.
 
Last edited:

C-Note

Hummingbird
Gold Member
I'm putting together data/info sheets on the various penny companies I'm investing, or thinking of investing in, to help me decide how much money to commit to them and when to sell. I'll post them here for what they're worth. I didn't include most financial info (p/e ratio, etc) because that data is easily accessible in the stock dashboard through my Vanguard account. On the data sheets are the "soft" info that I think will better help me decide on these companies, because most of them are years away from a chance at any real revenue.

I find it enjoyable to research these small companies, because it's like learning about a family. Most of these companies have less than 100 employees, who have worked for the company for years and are trying to make it profitable. It's like their hopes and dreams are sunk into the company's plan and vision. One thing you really notice about the small medicine companies is how speculative they really are. Most of them have their entire operation based on bringing only one or two drugs to market. If their drug fails, then they will fail, and 10+ years of their life's work will have gone nowhere.

AIM Immunotech 24 Mar 21

Outstanding Shares: 40.69M (Mar 2021 presentation says 47.8M)

Employees: 26

Market cap: 98.87M

Cash on hand: 39.6M

Two drugs in production and/or further development:

1. Ampligen (rintatolimod)

a. Chronic fatigue syndrome (CFS)- approved in Argentina (pending FDA export approval); Phase 3 in US; including COVID-19 survivors who contract the condition from their illness

b. Ovarian, colorectal, Carcinoma, breast, melanoma cancers- Phase 2

c. Pancreatic cancer- Phase 1, including Netherlands; orphan drug designation in Europe and US

d. Bladder cancer- pre-clinical

e. Intranasal prophylaxis- Phase 1

f. Cancer patients who contract COVID-19- Phase 1/2a

2. Alferon N Injection

a. Genital HPV (warts)- approved in US and Argentina (pending FDA manufacturing approval). According to the company this is the only approved drug worldwide for this affliction. But hasn't the HPV immunization made this moot?

b. IFN- approved in Argentina

c. External condylomata acuminata- approved in US but pending re-approval from FDA?

d. MERS- pre-clinical

e. Influenza A- pre-clinical

Notes:

All current revenue from clinical trial subsidies. Their manufacturing facility only producing the two drugs above for use in clinical trials. Having their own in-house manufacturing facility, rather than contractors, may increase their expenses. States in their March 2021 presentation that they are holding-back on upgrading production for commercial sales of Alferon because of belief that Ampligen holds more promise. On webpage basically begging for large partners to help them with commercial expansion. The Wikipedia entry for rintatolimod states that the company has tried, unsuccessfully, since 1988 to get the FDA to approve the drug (Ampligen) for various uses and has been hampered by a lack of sufficient clinical trials, for unknown reasons. CFS patients have lobbied FDA for its approval.

Possible that Ampligen might become the default drug for CFS after FDA approval w/ ~2m potential patients in US. Still, be careful not to sink too much money into this stock. Why has it taken them so long (30 years) to get Ampligen approved for anything? And why the focus on Argentina?

America’s Gold & Silver 24 Mar 2021

Outstanding Shares: 128.33M (Corp presentation says 130.7M)

Employees: 629

Market cap: 297.72M (Corp presentation says 341M)

Cash on hand: 4.7M (2020 financial statement)

Operations:

1. Relief Canyon, NV- 100% owned and operated. Gold. Began test production in January 2020 w/ full production Q2 2021. Projected 90-110k ounces for 2021. Six year initial mining life cycle. Open pit leach mine which keeps costs lower, but can be disrupted by bad weather as happened in Jan-Feb 21.

2. Galena Complex, ID- 60% owned. Silver & lead. Currently upgrading production with ECD 2022 with goal of 1.8-2M oz silver annually beginning that year.

3. Cosala’, Sinaloa, 100% owned and operated. No production, processing, or exploration since January 2020 due to criminal blockade.

a. Nuestro Senora mine (silver, zinc, copper, lead)

b. San Rafael mine (silver, zinc, lead)

c. Zone 120 exploration project (silver, copper)- main exploration focus of company

d. El Cajon exploration project (silver, copper)

4. San Felipe development project, Sonora- Doesn’t appear to currently be under active exploration.

Notes:

Loss of production at Cosala’, along with Covid restrictions, cut their revenue for 2020 in half. Government of Mexico will likely have to intervene, but no current indication that they will. Recent bear market in silver delayed development of the Galena Complex, but appears to be full steam ahead for right now. However, another silver price decline could halt it again, based on other companies’ activities (Spectrum, etc)

Relief Canyon appears to be solid w/ good potential at Galena and Cosala’. Company seems to be making successful effort to keep costs down and avoid having to issue new shares for financing. Watch market prices for gold and silver. Also, I have not attempted independent verification of company’s production claims and predictions or tried to find Mexican media reports on Cosala’ standoff.





aTyr Pharma 25 Mar 21

Outstanding Shares: 16.01m

Employees: 44

Market cap: 74.61m

Cash on hand: 17m (2020 financial statement); 31.7m ( cash and equivalents; 23 Mar 21 press release)

Products:

1. ATYR1923-

a. NRP2 treatment of lung inflammation, including interstitial (ILDs; immune disorder) and pulmonary sarcoidosis; Phase 1b/2a trials, including in partnership with Kyorin Pharm in Japan ($10M investment so far in aTyr; ATYR1923 is called KRP-R120 in Japan); results expected 3Q 2021

b. Severe respiratory complications from COVID-19 and other SARS/Corona viruses; Phase 2 trial completed March 2021 with 82% improvement in treated patients compared to placebo

2. ATYR2810- NRP2 treatment of certain solid tumors; pre-clinical (declared November 2020)

3. Additional tRNA synthetases and NRP2 targeting antibodies related to immunology, fibrosis and cancer; pre-clinical; holds 300+ intellectual property portfolio (including 220 patents) of protein compositions

a. Research funded by CSL Behring, a major pharmaceutical company in exchange for negotiable licensing rights

b. Subsidiary Pangu BioPharma conducts related research at Hong Kong University of Science and Technology, sponsored by Hong Kong government’s Innovation and Technology Commission (ITC); ITC contributed $750k to cover 50% of cost; aTyr will pay the remainder- Is the CCP using this to spy on aTyr’s technology?

Notes:

Paid off all long-term debt (loans) EOY 2020. Appears to be doing at well at keeping expenses low. Their agreement with Kyorin includes up to $165m in development awards (additional to $10m already received) and 3-15% royalties of future sales in Japan. However, the lung diseases targeted by ATYR1923 are, in general, rare, which may limit its marketability. Company claims ~600k potential patients in US (200k w/ pulmonary sarcoidosis); 3m worldwide, w/ potential sales of $2-3b.

Likely around 3 years until ATYR1923 ready for market, 10+ years for ATYR2810 (average time from creation to market for a drug is 12 years). Company states that it is their belief that they are the only org conducting marketable research and development of therapeutics based on novel functions of tRNA synthetases and NRP2 receptor biology, but that could change. Company contracts its drug production to 3rd party labs, not inhouse like AIM. Company’s webpage and literature is much more open, informative, and clear than AIM’s.
 

rainy

Kingfisher
AZFL almost hit .009 this past week. It's back down to the .005's but the volume and interest is there. Mexico is moving forward with legalization and their senate wants it legalized quickly and before the end of April.


Screen Shot 2021-03-28 at 3.04.46 PM.png

AZFL with its government and investor connections in Mexico is prime to be a major player in the industry down there. I think this hits multiple pennies within weeks and doesn't look back. Canadian MJ companies with AZFL may mirror are trading multi dollars.

A really cheap play I'm in is UBQU. Should be going current sometime soon but also a CBD play both here in the states and in Europe. Have an office in Madrid, growers across Europe and recently filed in the UK. Regularly updating their website.


It's unknown how big they have become which is part of the play here. Also have operations in FL and Colorado. Lots of PR two years ago. Launched an Ambassador program with revenue of 50K in it's 3rd month in Jan 2019. 8M revenue in 2018. With their presence in Europe and increasing operations in the US they could be much larger than they were in 2019. CEO Jim Ballas has been blogging regularly this year on the website. Patiently waiting for them to go current.

Do your own research but UBQU is the perfect example of the quiet before the storm, getting in before the filings and PR at which point you're chasing. If you're open to the risk, in the CBD industry which will grow 400% in the next few years here and in Europe where UBQU is, might consider throwing some money here.

Last play you might look into is MMEX. Hit .024 in Feb but is back in the .001's. It's a carbon and hydrogen company. CEO just announced plans in both TX and with Euro developers. Also have operations in South America.


Pointing these three plays out for those who accept a little risk and getting in early with considerable upside. I'm fairly confident AZFL and MMEX will be multi pennies within months with UBQU being the longer play. But OTC stocks must be current by Sept per the new SEC rules and I think UBQU is too big to not want to go current.

And let's hope the MM's stop holding down the market sometime soon. It's crazy what they're doing and getting away with with all the naked shorts. But that will end at some point. On the bright side it's a good opportunity to accumulate. I buy red, hold and sell longer term when green.

I don't really flip. Prefer investing in companies I like. So for capital gains tax purposes if you buy and hold one year plus one day I can't see these stocks not being considerably higher.
 
Last edited:

rainy

Kingfisher
Frankly I've never seen the market being manipulated like this. The MM's are recouping losses from the AMC/GME fiasco. They're naked shorting the entire market. Many of my stocks are being held down but they'll run at some point. The SEC is corrupt as hell.

You can see the manipulation live on LVL2 from the MM's like CDEL and JANE.

 

C-Note

Hummingbird
Gold Member
^^^^
I figured the recent downturns in OTC and penny stocks was due to day trading activities. If it's naked short selling also, then I'm not surprised. Actually, I haven't minded, because I've spent the last few days buying the dips in several of my stocks to get some dollar cost averaging done.

Anyway, here is my latest penny stock info sheet. This is another good example of how speculative small pharmaceutical company stocks are. If you only look at this company's corporate presentation, you would think that they're headed for tons of money because they have just gotten a unique drug onto the market. But, when you dig a little deeper, you see that they blew through tens of millions of dollars that last year or so to get it to market, so much so that they had to fire 40 employees (almost half their payroll!) this past November just to cut expenses a little. In four months time, to cover their losses, they also had to issue 40 million more shares, doubling their outstanding share pool and greatly diluting the value of their stock. Last year, when they announced their drug was going to market, their shares shot up from $1 to $4. But, within four months, the stock was back down to a dollar, where it has more-or-less stayed. Whoever bought it at 4 has seen their investment lose 75% quickly. Anyway, here we go...

Baudax Bio- BXRX 28 Mar 21

Outstanding Shares: 70.14m

Employees: 57

Market cap: 93.29m

Cash on hand: 30.3m (cash and equivalents; 2020 financial statement)

Products:

1. Anjeso Injection (Meloxicam)- This non-steroidal anti-inflammatory drug was patented in 1977 so, patent has expired, allowing Baudax to patent (expires May 2030) this new version. This version is intended to be administered by IV, once a day, mainly for post-operative surgical or other acute care patients in order to reduce their need for opioids or other analgesic pain killers. FDA approved in February 2020. Commercial availability and sales/distribution began in June 2020. Sales may be slow so far because of delays in elective surgeries due to Covid pandemic. $500k revenue from sales in 2020 against 1.7m cost of sales.

2. RP1000- Intermediate-acting neuromuscular blocking agent (NMBA) to produce complete paralysis for surgical patients. Phase I.

3. RP2000- Short-acting NMBA. Pre-clinical

4. RP3000- Reversal agent for RP1000 and 2000. Developed in conjunction.

5. Dexmedetomidine inhalant- Original is an injectable sedative. Baudax developing nasal spray version with own patent, but paying licensing fees to Orion, the original developer. Pre-clinical. Company states in financial statement that it is seeking a partner to help finance additional development, probably because they're short on money.

Notes:

Company licenses the RP drugs from Cornell, owing them annual fees plus royalties of future sales. It appears that Baudax’ strategy is to improve or create variations of existing drugs, rather than inventing completely new drugs. When the company announced commercial production and availability for Anjeso in June 2020, stock price jumped to almost $4, but then fell back to close to $1 in October, where it has remained. Why? Likely due to slow sales, increased expenses, and selling of additional shares, which has diluted their value. The company fired 40 staff in November 2020, mainly from marketing team, for cost cutting. Sold 11m retail shares in Feb 2021 at $1.60. Plus, sold 10m shares each month (30m total) from November 2020 to January 2021 to institutional investors, apparently to cover steep losses incurred in 2020 (76.1m vs 32.6m for 2019). Uses 3rd party contractor to manufacture Anjeso.

Non-opioid competitor drugs to Anjeso include IV Ketorolac (generic), Ofirmev (generic acetaminophen), Caldolor (generic Ibuprofen), and Exparel (generic Bupivacaine). Company is challenged to develop market demand for Anjeso to compensate for steep expenses incurred in getting it to market. Could be several years, at a minimum, before seeing a net profit, and perhaps never if they can’t get enough hospitals to start using it. It seems most hospitals, especially large chains, already have established pain drug protocols based on relationships with larger drug companies. Risky stock that would generate a good return if Anjeso use takes off, but that is definitely not a given.
 
Last edited:

aeroektar

Pelican
Sold AZFL when it hit .008 last week, thanks for mentioning that rainy, may enter it again if it gets to around .0045 this week, it should go up again when they go current or release any good news about the opening of a production facility this spring.

Also took positions on Denison Mines (dnn) and Impact Silver (isvlf) while everything was red Friday. Looking to take a position on High Tide (hitif) if it gets back near ¢6. Looks like all of these have a lot of room to grow.

Holding PHIL, have a sell order at .0065 should be able to go above that if they drop good news or go current.
 
Top